Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Revisiting NICE's approval of 'breakthrough' drugs palbociclib and ribociclib

Claims of cancer drugs’ survival benefits must be accurate. To avoid fashion and fads, we must carefully examine the clinical and economic implications of newly approved cancer drugs before we seat them on the ‘breakthrough’ throne.

In November 2017, the National Institute for Health and Care Excellence (NICE) approved palbociclib and ribociclib (for post-menopausal patients), for medical use in combination with an aromatase inhibitor, in women in the UK with hormone (oestrogen or progesterone) receptor-positive / human epidermal growth factor receptor 2 (HER2)-negative, locally advanced breast cancer[1].

Examining the clinical implications

1. An average of 10-month improvement in progression-free survival (PFS) is noted.

2. The two drugs ‘might be’ beneficial and to ‘only’ 8,000 British women per year.

3. It is argued that the drugs would delay the need for chemotherapy and avoid the therapy’s unpleasant adverse effects (AEs), but palbociclib and ribociclib are not free from AEs.

4. Several trials showed AEs of grade 3/4 neutropenia with palbociclib in combination treatments. This may give lower or non-adherence. The NHS loses £500m a year to non-adherence[2].

5. During PALOMA trials with palbociclib, many patients underwent dose reduction and discontinuation. Medical professionals recommend dose reduction to ameliorate AEs. Research shows dose reduction and interruption with palbociclib negatively affects patient outcomes in regard to PFS, overall survival and onset to subsequent therapy[3]. Dose reduction and discontinuation also lead to medication wastage because prior prescription doses cannot be retained for later or split. This would affect pharmacy costs, constrain the NHS budget, and allocate funds away from critical issues in healthcare, which was shown to increase the mortality gap in UK[4].

6. At the European Society for Medical Oncology Congress 2017, I attended the MONARCH III trial results session, which detailed a new member of CDK4/6 inhibitors’ second generation. Abemaciclib is more selective than the palbociclib and ribociclib, and the AE profile is expected to be better. Palbociclib and ribociclib are outdated within their generation.

Assessing the economic implications

1. The less clinically established drug, ribociclib, is approved for a third of the price per capsule compared with that of palbociclib, despite the similar mechanism of action and clinical outcomes.

2. The approval alleviates pressure from the Cancer Drugs Fund, and drives greater value from taxpayers’ increasing investment in cancer therapies; however, confidentiality arouses curiosity.

The drugs may seem beneficial, but ‘breakthrough’ is a loaded word reserved for ‘sustainable’ cancer drugs[5]. Research has shown that drugs not approved by the US Food and Drug Administration were heralded as ‘breakthrough’ in the press 50% of the time[6]. This leads to false and bias connotations, especially by patients.

NICE’s approval of palbociclib and ribociclib is a step in the right direction to possibly prolonging the lives of many women. But the ‘breakthrough’ description must be revisited and put into clinical, social and economic context.

Balkees Abderrahman,

Postdoctoral fellow 

University of Texas MD Anderson Cancer Center

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20204074

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.